Frank Osterkamp

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results

Richard P. Baum, Christiane Schuchardt, Aviral Singh et al. · Journal of Nuclear Medicine · 2021 · 327 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2022 · 254 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

¹⁷⁷Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results

Richard P. Baum, Aviral Singh, Christiane Schuchardt et al. · Journal of Nuclear Medicine · 2017 · 88 citations · Full text

Medicine, Oncology, Pharmacology +13

Design and Synthesis of a New Class of Selective Integrin α5β1 Antagonists

Roland Stragies, Frank Osterkamp, Gunther Zischinsky et al. · Journal of Medicinal Chemistry · 2007 · 63 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Proof of Therapeutic Efficacy of a¹⁷⁷Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model

Jörg Schulz, Martin Rohracker, Marvin Stiebler et al. · Journal of Nuclear Medicine · 2017 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17